NasdaqGS - Delayed Quote USD

Ionis Pharmaceuticals, Inc. (IONS)

Compare

34.01

+0.07

(+0.21%)

At close: 4:00 PM EST

34.46

+0.45

(+1.32%)

After hours: 5:18 PM EST

Report Name

Direction

Rating

Price Target

Morningstar ?Analyst Report ?last month

Ionis Pharmaceuticals, Inc.: Ionis Earnings: Following In-Line Quarter, We Raise Fair Value Estimate to $69 on Angelman Potential

Direction

Rating

Price Target

Morningstar ?Analyst Report ?6 months ago

Ionis Pharmaceuticals, Inc.: Ionis Earnings: Maintaining Our $62 Fair Value Estimate as Series of New Launches Begins

Direction

Rating

Price Target

Argus ?Top/Bottom Insider Activity ?7 months ago

Daily – Vickers Top Buyers & Sellers for 04/18/2024

Direction -

Rating -

Price Target -

Morningstar ?Analyst Report ?8 months ago

Ionis Pharmaceuticals, Inc.: Ionis Earnings: Maintaining $62 Fair Value Estimate; Wainua a Precursor to Two Independent Launches

Direction

Rating

Price Target

Morningstar ?Analyst Report ?last year

Ionis Pharmaceuticals, Inc.: Ionis Earnings: Third-Quarter Results Show Growing Late-Stage Pipeline; Shares Remain Undervalued

Direction

Rating

Price Target

Morningstar ?Analyst Report ?last year

Ionis Pharmaceuticals, Inc.: Ionis Earnings: Results Show Late-Stage Pipeline on Track; Shares Remain Undervalued

Direction

Rating

Price Target

Morningstar ?Analyst Report ?last year

Ionis Pharmaceuticals, Inc.: Ionis Earnings: String of Late-Stage Pipeline Data Begins in the Second Half of 2023

Direction

Rating

Price Target

Morningstar ?Analyst Report ?last year

Ionis Pharmaceuticals, Inc.: Maintaining Our $62 Ionis FVE as R&D Expenses Ramp Ahead of Bigger Phase 3 Readouts

Direction

Rating

Price Target

Morningstar ?Analyst Report ?last year

Ionis Pharmaceuticals, Inc.: Maintaining Our $62 FVE for Ionis Following In Line Q3; Late-Stage Pipeline Advancing

Direction

Rating

Price Target

Morningstar ?Analyst Report ?2 years ago

Ionis Pharmaceuticals, Inc.: Antisense Technology Supports Ionis' Large Late-Stage Pipeline and Narrow Moat

Direction

Rating

Price Target

Morningstar ?Analyst Report ?2 years ago

Ionis Pharmaceuticals, Inc.: Ionis Shares Remain Undervalued Following Q2 as Late-Stage Pipeline Advances and Expands

Direction

Rating

Price Target

Morningstar ?Analyst Report ?2 years ago

Ionis Pharmaceuticals, Inc.: Maintaining Our $62 Fair Value Estimate for Ionis Following Positive Phase 3 Eplontersen Data

Direction

Rating

Price Target

Morningstar ?Analyst Report ?2 years ago

Ionis Pharmaceuticals, Inc.: Maintaining $62 Fair Value Estimate for Ionis Following In-Line Q1 Results as Data Readouts Approach

Direction

Rating

Price Target

Morningstar ?Analyst Report ?2 years ago

Ionis Pharmaceuticals, Inc.: Research & Development Is Driving Medical Breakthroughs and Exponential Growth Opportunities

Direction

Rating

Price Target

Morningstar ?Analyst Report ?2 years ago

Ionis Pharmaceuticals, Inc.: Ionis Diving Back Into the Red in 2022, but We See Its Pipeline as Significantly Undervalued

Direction

Rating

Price Target

Morningstar ?Analyst Report ?2 years ago

Ionis Pharmaceuticals, Inc.: Maintaining Our $62 Fair Value Estimate for Ionis Following Eplontersen Licensing Deal

Direction

Rating

Price Target

Morningstar ?Analyst Report ?2 years ago

Ionis Pharmaceuticals, Inc.: Maintaining Our $62 FVE and 2021 Forecast for Ionis; Data Catalysts Ramping Up in 2022

Direction

Rating

Price Target

ALNY Alnylam Pharmaceuticals, Inc.

244.89

-0.77%

ARWR Arrowhead Pharmaceuticals, Inc.

18.54

+1.42%

BMRN BioMarin Pharmaceutical Inc.

64.26

+1.28%

CYTK Cytokinetics, Incorporated

49.10

+3.00%

BBIO BridgeBio Pharma, Inc.

23.42

+0.77%

INCY Incyte Corporation

71.72

+1.89%

LEGN Legend Biotech Corporation

40.94

+2.99%

BPMC Blueprint Medicines Corporation

94.15

-2.56%

BGNE BeiGene, Ltd.

190.51

-2.08%

PTGX Protagonist Therapeutics, Inc.

46.46

+11.55%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Ionis Pharmaceuticals, Inc. (IONS)

Research Reports: IONS

Ionis Pharmaceuticals, Inc.: Ionis Earnings: Following In-Line Quarter, We Raise Fair Value Estimate to $69 on Angelman Potential

Ionis Pharmaceuticals, Inc.: Ionis Earnings: Maintaining Our $62 Fair Value Estimate as Series of New Launches Begins

Daily – Vickers Top Buyers & Sellers for 04/18/2024

Ionis Pharmaceuticals, Inc.: Ionis Earnings: Maintaining $62 Fair Value Estimate; Wainua a Precursor to Two Independent Launches

Ionis Pharmaceuticals, Inc.: Ionis Earnings: Third-Quarter Results Show Growing Late-Stage Pipeline; Shares Remain Undervalued

Ionis Pharmaceuticals, Inc.: Ionis Earnings: Results Show Late-Stage Pipeline on Track; Shares Remain Undervalued

Ionis Pharmaceuticals, Inc.: Ionis Earnings: String of Late-Stage Pipeline Data Begins in the Second Half of 2023

Ionis Pharmaceuticals, Inc.: Maintaining Our $62 Ionis FVE as R&D Expenses Ramp Ahead of Bigger Phase 3 Readouts

Ionis Pharmaceuticals, Inc.: Maintaining Our $62 FVE for Ionis Following In Line Q3; Late-Stage Pipeline Advancing

Ionis Pharmaceuticals, Inc.: Antisense Technology Supports Ionis' Large Late-Stage Pipeline and Narrow Moat

Ionis Pharmaceuticals, Inc.: Ionis Shares Remain Undervalued Following Q2 as Late-Stage Pipeline Advances and Expands

Ionis Pharmaceuticals, Inc.: Maintaining Our $62 Fair Value Estimate for Ionis Following Positive Phase 3 Eplontersen Data

Ionis Pharmaceuticals, Inc.: Maintaining $62 Fair Value Estimate for Ionis Following In-Line Q1 Results as Data Readouts Approach

Ionis Pharmaceuticals, Inc.: Research & Development Is Driving Medical Breakthroughs and Exponential Growth Opportunities

Ionis Pharmaceuticals, Inc.: Ionis Diving Back Into the Red in 2022, but We See Its Pipeline as Significantly Undervalued

Ionis Pharmaceuticals, Inc.: Maintaining Our $62 Fair Value Estimate for Ionis Following Eplontersen Licensing Deal

Ionis Pharmaceuticals, Inc.: Maintaining Our $62 FVE and 2021 Forecast for Ionis; Data Catalysts Ramping Up in 2022

Related Tickers